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Identity 
Other names: ARC (Apoptosis Repressor with 
CARD); CARD2; MYP; NOP; NOP30 
HGNC (Hugo): NOL3 
Location: 16q22.1 
Note 
The correct name for the locus is NOL3. Sometimes, 
however, the gene is referred to by  
names of the putative encoded proteins: 
ARC (Apoptosis Repressor with CARD) CARD 
denotes a Caspase Recruitment Domain. The ARC 
protein resides in the cytoplasm and nucleoplasm, not 
nucleolus. 
MYP is an older name for ARC that is currently not 
used. References to this locus as MYC are incorrect 
and probably represent typographical errors of MYP. 
NOL3 is distinct from any of the myc loci. 
 
The NOL3 gene is located on the long arm of human chromosome 16. The gene consists of 4 small exons (exons denoted above as 
thick boxes) and 3 small introns. The translational start site is in exon 2. Alternative splicing occurs between exons 2 and 3. This involves 
two splice donors separated by 10 nucleotides in exon 2 connecting to a single splice acceptor in exon 3 (Stoss et al., 1999). Because 
the separation between the splice donors, 10 nucleotides, is not an exact multiple of 3, alternative splicing results in two open reading 
frames distal to the splice acceptor. Because of this frame shift, the C-terminus of the two encoded proteins differ as do their stop 
codons, each of which is in exon 4. One transcript is translated into ARC (Apoptosis Repressor with CARD (Caspase Recruitment 
Domain)) (Koseki et al., 1998). MYP is an earlier name for ARC that is no longer in use (Geertman et al., 1996). The other transcript 
encodes a putative protein called NOP30 (Nucleolar Protein of 30 kD). ARC and putative NOP30 proteins share a common N-terminus 
containing the CARD. Their C-termini differ, however, with ARC containing multiple P/E repeats (acidic) and putative NOP30 containing 
R/S repeats (basic). While ARC transcripts are present in a variety of human and mouse cell types, NOP30 transcripts are present in 
human, but not mouse (L. Wu and R. Kitsis, unpublished). Endogenous ARC protein resides in the cytoplasm and nucleoplasm of certain 
human and mouse cell types (discussed below). In contrast, the existence of endogenous NOP30 protein has not been demonstrated in 
any cell type of any species. When the cDNA encoding NOP30 is exogenously expressed, the encoded protein is in the nucleolus and 
nucleoplasm (Stoss et al., 1999). 
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NOP30. In some species, alternative splicing gives rise 
to a transcript encoding a putative protein NOP30, 
rather than ARC. When the cDNA for NOP30 is 
expressed exogenously, the resulting protein is 
predominantly nucleolar - hence the origin of the gene 
name: nucleolar protein 3. Impo-rtantly, however, 
endogenous NOP30 protein has not been demonstrated 
in any cells of any species. 
DNA/RNA 
Description 
The NOL3 gene is located on human chromosome 
16q21-23. The gene contains 4 exons and 3 introns 
spanning 1757 bp. 
Transcription 
The coordinate of the first nucleotide of exon 1 is 
65,765,371 bp from pter, and that of the last nucleotid  
of exon 4 is 65,767,127 bp. Alternative splicing takes 
place between exons 2 and 3. In exon 2, the splice 
donor of the NOP30 transcript is 10 bp upstream of the 
splice donor of the ARC transcript. Both transcripts use 
a common splice acceptor in exon 3. 
Protein 
Note 
The start of translation is in exon 2 (prior to the 
alternative splice donors). Alternative splicing causes a 
frame shift resulting in transcripts encoding proteins 
with different C-termini and separate stop codons i 
exon 4. The stop codon for ARC is 43 bp upstream of 
that of NOP30. 
 
Alternatively spliced transcripts of NOL3 lead to two different 
proteins, ARC (blue) and NOP30 (red). These proteins each 
contain an N-terminal CARD (first 95 amino acids identical), but 
have different C-termini. The C-terminus of ARC is rich in 
prolines and glutamic acids, whereas the C-terminus of NOP30 
is rich in serines and arginines. 
Description 
Human ARC protein contains 208 amino acids with Mr 
22,629 Da. The protein usually runs at a slower 
mobility on SDS-PAGE most likely due to the 
enrichment of proline residues in the C-terminal 
domain. NOP30 contains 219 amino acids with Mr 
24,327 Da. 
Expression 
Under normal conditions, ARC mRNA and protein is 
present predominantly in cardiac myocytes, skeletal 
myocytes, and neurons (Koseki et al., 1998; Abmayr et 
al., 2004; Geertman et al., 1996; Engidawork et al., 
2001). ARC protein is also markedly increased in 
primary human epithelial cancers of the breast, colon, 
ovary, and cervix (Mercier et al., 2005; Mercier et al., 
2008). NOP30 transcripts are present in some human 
cell types but have not been detected in mouse cells. 
Endogenous NOP30 protein has not been demonstrated 
in cells of any species. 
Localisation 
Endogenous ARC protein is present in the cytoplasm 
and nucleoplasm (Mercier et al., 2005). As above, th  
localization of endogenous NOP30 protein has not been 
investigated. Exogenously expressed NOP30 protein 
localizes in the nucleolus and nucleoplasm. 
Function 
The function of endogenous NOP30 is not known. 
Exogenous NOP30 interacts with SFRS9/SRp30C and 
NPM1 and may influence splicing (Stoss et al., 1999). 
ARC is an endogenous inhibitor of apoptosis that is 
unique in its ability to antagonize both the extrinsic 
(death receptor) and the intrinsic (mitochondria/ER) 
death pathways (Nam et al., 2004; Gustafsson et al., 
2004; Koseki et al., 1998). ARC inhibits the extrinsic 
pathway by interfering with DISC (Death Inducing 
Signaling Complex) formation. This is accomplished 
by the direct interaction of the ARC CARD with the 
death domains (DD) of Fas and FADD, and with the 
death effector domain (DED) of procaspase-8. These 
death-fold interactions are novel in that they are 
heterotypic in contrast to the usual homotypic death-
fold interactions. ARC inhibits the intrinsic pathway 
through at least two mechanisms. First, the direct 
interaction between the ARC CARD and the C-
terminus of Bax inhibits death stimulus-induced Bax 
conformational activa-tion and translocation to the 
mitochondria. Second, direct interaction between the 
ARC C-terminal domain with the p53 tetramerization 
domain inhibits p53 tetramerization (Foo et al., PNAS, 
2007). This, in turn, disables p53 transcriptional 
function and exposes a p53 nuclear export signal that 
relocates p53 to the cytoplasm. 
Nothing is known about the regulation of NOP30. 
The regulation of ARC is complex. ARC protein 
abundance decreases rapidly and dramatically in 
response to hypoxia and oxidative stress (e.g. ischemia-
reperfusion) (Ekhterae et al., 1999; Neuss et al., 2001; 
Nam et al., 2007). These decreases result from 
increased degradation of ARC protein via the ubiquitin-
proteasomal pathway (Nam et al., 2007). The E3 ligase 
MDM2 may play a role in ARC degradation in this 
scenario (Foo et al., JBC, 2007), but this role is 
probably indirect (L. Wu and R. Kitsis, unpublished 
data). Decreases in ARC protein abundance in response 
to hypoxia appear to be regulated by p53 repression of 
nol3 transcription (Li et al., 2008). Apart from ARC 
protein abundance, the activity of ARC is also 
regulated  
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Regulation of the extrinsic (death receptor) and intrinsic (mitochondria/ER) apoptosis pathways by ARC. Not shown are ARC interactions 
with and regulation of p53. 
 
post-translationally: dephosphorylation of threonine 
149 decreases the anti-apoptotic activity of ARC (Tan 
et al., 2008). 
Homology 
ARC is highly conserved among mammals. There is 
approximately 85% identity both at the amino acid an  
the nucleotide level among human, rat, mouse, dog, and 
bovine ARC. Interestingly, an ARC homolog has yet to 
be identified in Danio rerio, Drosophila melanogaster, 




Increased levels of ARC protein have been observed in 
the epithelium of primary human breast, colon, ovarian, 
and cervical cancers (Mercier et al., 2005; Mercier et 
al., 2008). Increased levels of both ARC RNA and 
protein have been observed in renal cell carcinoma 
(Heikaus et al., 2008). 
Prognosis 
ARC overexpression in a breast cancer cell line 
increases resistance to chemotherapy and radiation 
(Mercier et al., 2005; Wang et al., 2009). In a mela-
noma cell line, ARC overexpression causes increased 
resistance to endoplasmic reticulum stress-induced 
caspase-8 activation (Chen et al., 2008). 
Myocardial infarction, myocardial 
ischemia-reperfusion 
Prognosis 
ARC plays an important role in regulating heart muscle 
damage during myocardial infarction. Endogenous 
ARC protein undergoes rapid protea-somal degradation 
during myocardial ischemia-reperfusion (Nam et al.,
2007). This decrease in ARC abundance is causally 
linked with the subsequent cell death (Nam et al., 
2004). Accordingly, transgenic overexpression of ARC 
in vivo decreases the size of myocardial infarctions 
(Gustafsson et al., 2002; Pyo et al., 2008; S. Jha and R. 
Kitsis, unpublished data). As would be predicted, 
knockout of ARC has been reported to result in larger 
infarcts (Donath et al., 2006). However, the 
aforementioned knockout studies were performed on 
only small numbers of mice on a mixed genetic 
background. Subsequent knockout studies involving 
large numbers of mice on several pure genetic 
backgrounds have not demonstrated larger infarcts in 
ARC-/- mice subjected to ische-mia-reperfusion (J. 
Saurabh, S. Y. Ji, and R. Kitsis, unpublished data). This 
is probably due to the dramatic rapid degradation of 




ARC protein levels decrease during heart failure. 
Moreover, knockout of ARC exacerbates patholo-gical 
cardiac remodeling in response to hemody-namic 
overload, a model of heart failure (Donath et al., 2006). 
Neuropathology (several individual 
entities) 
Prognosis 
The protein level of ARC is increased in the frontal 
cortex of patients with Alzheimer's disease 
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(Engidawork et al., 2001). During ischemic injury of 
the brain, there is a decrease in ARC protein in 
hippocampal neurons (Hong et al., 2003). Other studies 
have also shown that caloric restriction increases 





Geertman R, McMahon A, Sabban EL. Cloning and 
characterization of cDNAs for novel proteins with glutamic 
acid-proline dipeptide tandem repeats. Biochim Biophys Acta. 
1996 May 2;1306(2-3):147-52 
Koseki T, Inohara N, Chen S, Núñez G. ARC, an inhibitor of 
apoptosis expressed in skeletal muscle and heart that interacts 
selectively with caspases. Proc Natl Acad Sci U S A. 1998 Apr 
28;95(9):5156-60 
Ekhterae D, Lin Z, Lundberg MS, Crow MT, Brosius FC 3rd, 
Núñez G. ARC inhibits cytochrome c release from 
mitochondria and protects against hypoxia-induced apoptosis 
in heart-derived H9c2 cells. Circ Res. 1999 Dec 9;85(12):e70-7 
Stoss O, Schwaiger FW, Cooper TA, Stamm S. Alternative 
splicing determines the intracellular localization of the novel 
nuclear protein Nop30 and its interaction with the splicing 
factor SRp30c. J Biol Chem. 1999 Apr 16;274(16):10951-62 
Engidawork E, Gulesserian T, Yoo BC, Cairns N, Lubec G. 
Alteration of caspases and apoptosis-related proteins in brains 
of patients with Alzheimer's disease. Biochem Biophys Res 
Commun. 2001 Feb 16;281(1):84-93 
Neuss M, Monticone R, Lundberg MS, Chesley AT, Fleck E, 
Crow MT. The apoptotic regulatory protein ARC (apoptosis 
repressor with caspase recruitment domain) prevents oxidant 
stress-mediated cell death by preserving mitochondrial 
function. J Biol Chem. 2001 Sep 7;276(36):33915-22 
Gustafsson AB, Sayen MR, Williams SD, Crow MT, Gottlieb 
RA. TAT protein transduction into isolated perfused hearts: 
TAT-apoptosis repressor with caspase recruitment domain is 
cardioprotective. Circulation. 2002 Aug 6;106(6):735-9 
Hong YM, Jo DG, Lee JY, Chang JW, Nam JH, Noh JY, Koh 
JY, Jung YK. Down-regulation of ARC contributes to 
vulnerability of hippocampal neurons to ischemia/hypoxia. 
FEBS Lett. 2003 May 22;543(1-3):170-3 
Shelke RR, Leeuwenburgh C. Lifelong caloric restriction 
increases expression of apoptosis repressor with a caspase 
recruitment domain (ARC) in the brain. FASEB J. 2003 
Mar;17(3):494-6 
Abmayr S, Crawford RW, Chamberlain JS. Characterization of 
ARC, apoptosis repressor interacting with CARD, in normal 
and dystrophin-deficient skeletal muscle. Hum Mol Genet. 
2004 Jan 15;13(2):213-21 
Gustafsson AB, Tsai JG, Logue SE, Crow MT, Gottlieb RA. 
Apoptosis repressor with caspase recruitment domain protects 
against cell death by interfering with Bax activation. J Biol 
Chem. 2004 May 14;279(20):21233-8 
Nam YJ, Mani K, Ashton AW, Peng CF, Krishnamurthy B, 
Hayakawa Y, Lee P, Korsmeyer SJ, Kitsis RN. Inhibition of 
both the extrinsic and intrinsic death pathways through 
nonhomotypic death-fold interactions. Mol Cell. 2004 Sep 
24;15(6):901-12 
Mercier I, Vuolo M, Madan R, Xue X, Levalley AJ, Ashton AW, 
Jasmin JF, Czaja MT, Lin EY, Armstrong RC, Pollard JW, 
Kitsis RN. ARC, an apoptosis suppressor limited to terminally 
differentiated cells, is induced in human breast cancer and 
confers chemo- and radiation-resistance. Cell Death Differ. 
2005 Jun;12(6):682-6 
Donath S, Li P, Willenbockel C, Al-Saadi N, Gross V, Willnow 
T, Bader M, Martin U, Bauersachs J, Wollert KC, Dietz R, von 
Harsdorf R. Apoptosis repressor with caspase recruitment 
domain is required for cardioprotection in response to 
biomechanical and ischemic stress. Circulation. 2006 Mar 
7;113(9):1203-12 
Foo RS, Chan LK, Kitsis RN, Bennett MR. Ubiquitination and 
degradation of the anti-apoptotic protein ARC by MDM2. J Biol 
Chem. 2007 Feb 23;282(8):5529-35 
Foo RS, Nam YJ, Ostreicher MJ, Metzl MD, Whelan RS, Peng 
CF, Ashton AW, Fu W, Mani K, Chin SF, Provenzano E, Ellis I, 
Figg N, Pinder S, Bennett MR, Caldas C, Kitsis RN. Regulation 
of p53 tetramerization and nuclear export by ARC. Proc Natl 
Acad Sci U S A. 2007 Dec 26;104(52):20826-31 
Nam YJ, Mani K, Wu L, Peng CF, Calvert JW, Foo RS, 
Krishnamurthy B, Miao W, Ashton AW, Lefer DJ, Kitsis RN. 
The apoptosis inhibitor ARC undergoes ubiquitin-proteasomal-
mediated degradation in response to death stimuli: 
identification of a degradation-resistant mutant. J Biol Chem. 
2007 Feb 23;282(8):5522-8 
Chen LH, Jiang CC, Watts R, Thorne RF, Kiejda KA, Zhang 
XD, Hersey P. Inhibition of endoplasmic reticulum stress-
induced apoptosis of melanoma cells by the ARC protein. 
Cancer Res. 2008 Feb 1;68(3):834-42 
Heikaus S, Kempf T, Mahotka C, Gabbert HE, Ramp U. 
Caspase-8 and its inhibitors in RCCs in vivo: the prominent 
role of ARC. Apoptosis. 2008 Jul;13(7):938-49 
Li YZ, Lu DY, Tan WQ, Wang JX, Li PF. p53 initiates apoptosis 
by transcriptionally targeting the antiapoptotic protein ARC. Mol 
Cell Biol. 2008 Jan;28(2):564-74 
Mercier I, Vuolo M, Jasmin JF, Medina CM, Williams M, 
Mariadason JM, Qian H, Xue X, Pestell RG, Lisanti MP, Kitsis 
RN. ARC (apoptosis repressor with caspase recruitment 
domain) is a novel marker of human colon cancer. Cell Cycle. 
2008 Jun 1;7(11):1640-7 
Pyo JO, Nah J, Kim HJ, Chang JW, Song YW, Yang DK, Jo 
DG, Kim HR, Chae HJ, Chae SW, Hwang SY, Kim SJ, Kim HJ, 
Cho C, Oh CG, Park WJ, Jung YK. Protection of 
cardiomyocytes from ischemic/hypoxic cell death via Drbp1 
and pMe2GlyDH in cardio-specific ARC transgenic mice. J Biol 
Chem. 2008 Nov 7;283(45):30707-14 
Tan WQ, Wang JX, Lin ZQ, Li YR, Lin Y, Li PF. Novel cardiac 
apoptotic pathway: the dephosphorylation of apoptosis 
repressor with caspase recruitment domain by calcineurin. 
Circulation. 2008 Nov 25;118(22):2268-76 
Wang JX, Li Q, Li PF. Apoptosis repressor with caspase 
recruitment domain contributes to chemotherapy resistance by 
abolishing mitochondrial fission mediated by dynamin-related 
protein-1. Cancer Res. 2009 Jan 15;69(2):492-500 
This article should be referenced as such: 
Kung G, McKimpson W, Kitsis RN. NOL3 (nucleolar protein 3 
(apoptosis repressor with CARD domain)). Atlas Genet 
Cytogenet Oncol Haematol. 2010; 14(4):400-403. 
